Novo Nordisk stock steadies after JPMorgan lifts its target
Published on 08/25/2026 at 20:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock is steady after JPMorgan lifted its price target to DKK 275 from DKK 250 and raised its 2026 sales expectations, while Novo Nordisk A/S reported Q2 2026 adjusted sales of DKK 78,488 million.
The move follows a fresh analyst update on August 25, 2026, and gives investors two numbers to weigh at once: a higher target and a still-cautious Neutral rating.
JPMorgan narrows the gap
JPMorgan now sees the Danish drugmaker at DKK 275, while the average target shown in market data stands at DKK 309.73, a gap of DKK 34.73 above the new call. The same trading snapshot shows Novo Nordisk shares last closed at DKK 299.25 on August 24, 2026, leaving the stock above JPMorgan's target and below the average view.
That pricing backdrop matters because the shares had a five-day change of 2.34% and a year-to-date move still in positive territory, according to the same market snapshot. For investors, the message is simple: the stock is trading with a high bar already built in.
Q2 figures still matter
The most recent reported quarter remains Q2 2026, when adjusted operating profit reached DKK 33,389 million and rose 11% at constant exchange rates versus the prior-year quarter. Adjusted sales climbed 7% at constant exchange rates to DKK 78,488 million, while reported operating profit was DKK 27,061 million.
Those figures frame the debate after the target move. Sales growth is still positive, but the gap between adjusted and reported profit shows how much one-off items and impairment charges still shape the headline view.
What the market is pricing
The latest comparison is not just between one bank and the stock price. JPMorgan's DKK 275 target sits 8.1% below the DKK 299.25 Copenhagen close from August 24, 2026, while the wider average target of DKK 309.73 sits 3.5% above that close.
That spread suggests a divided market view rather than a clean consensus. Novo Nordisk is still being judged on whether its growth outlook can justify the valuation after the latest quarter.
Ozempic and the pipeline
Ozempic remains the flagship product, and its weight-loss and diabetes franchise still anchors the investment case. The product mix matters because GLP-1 volume growth helped lift Q2 2026 adjusted operating profit to DKK 33,389 million.
That makes the pipeline and product execution more important than a single target change. Investors are watching whether the company can keep converting demand into profit at a pace that supports the share price.
Price and venue
On Nasdaq Copenhagen, Novo Nordisk shares last closed at DKK 299.25 on August 24, 2026.
Fact box
Company: Novo Nordisk A/S
ISIN: DK0060534915
Ticker: NOVO B
Exchange: Nasdaq Copenhagen
Price (as of August 24, 2026): DKK 299.25
Market cap: DKK 1.33 trillion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: OMX Copenhagen 25
More on Novo Nordisk stock
Ozempic is the best-known product in the company's diabetes and obesity portfolio, and it remains the clearest lens on sales momentum and margin pressure.
